CliffBio
small molecule

AKTIPAK

BENZOYL PEROXIDE; ERYTHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyBiofrontera →See this company's full patent-cliff portfolio

Drug detail

Brand nameAKTIPAK
Active ingredientBENZOYL PEROXIDE; ERYTHROMYCIN
Strength5%;3%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalNovember 2000
Marketing statusDISCN

More from Biofrontera

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.